ZURICH, Nov 28 (Reuters) - The European Commission has approved Novartis AG’s (NOVN.VX: Quote, Profile, Research) Tasigna drug for use in chronic myeloid leukaemia (CML) for patients who no longer respond to Glivec, the Swiss company said on Wednesday.
